Lung Cancer Risk Associated With New Solid Nodules in the National Lung Screening Trial
as new or preexisting on the basis of comparison with findings from prior LDCT screening examinations.
Subjects were tracked for lung cancer incidence and mortality. We examined the incidence
of new nodules and their associated lung cancer risk by nodule size (i.e., mean diameter).
As low-dose CT (LDCT) lung cancer screening moves into routine clinical
practice, evaluation of nodules identified as new becomes critical. We examine the frequency
and clinical outcomes of new lung nodules reported at the two postbaseline annual screening
examinations (hereafter referred to as postbaseline time 1 [T1] and time 2 [T2]), compared
with those detected at baseline in the National Lung Screening Trial (NLST).
Zhao Shijun Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Li Hongjia. Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Hebei Cancer Hospital, Chinese Academy of Medical Sciences, Langfang, 065001, China
Yang DING. Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China